GlassScriptPhysician profile
Sarada Vemareddy
NPI 1407049505
$4,375.62
in general payments reported to CMS, 2019-2025
26 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $1,018 · 2021: $732 · 2022: $102 · 2023: $519 · 2024: $750 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.71 |
| Education | $133.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $748.77 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $627.71 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $545.49 | 2019-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $444.64 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $346.09 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $301.17 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.45 | 2019-2021 | |
| Amarin Pharma, INC. | $184.06 | 2019-2020 | |
| Pfizer INC. | $122.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $118.87 | 2020-2025 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $111.40 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $94.29 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $82.29 | 2019-2021 | |
| Esperion Therapeutics, INC. | $78.11 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $69.49 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $60.86 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $46.46 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $43.74 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $42.79 | 2023-2024 | Gvoke Hypopen |
| Mylan Specialty L.P. | $21.46 | 2020 | |
| Philips North America LLC | $18.95 | 2022 | |
| Sumitomo Pharma America, INC. | $18.54 | 2025 | Gemtesa |
| Ferring Pharmaceuticals INC. | $18.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.62 | 2024 | |
| Boston Scientific Corporation | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarada Vemareddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.